# NCT05737706 (NCT05737706)

> Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05737706
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Mirati Therapeutics Inc.
- Conditions: Solid Tumor; Advanced Solid Tumor; Non-small Cell Lung Cancer; Colo-rectal Cancer; Pancreatic Adenocarcinoma
- Interventions: MRTX1133
- Enrollment: 63
- Primary outcome: Phase 1: Number of Patients who Experience Dose-Limiting Toxicity
- Primary outcome: Phase 1/1b: Number of patients who experience a treatment-related adverse event
- Primary outcome: Phase 2: Objective response rate (ORR)
- Primary outcome: Phase 2: Duration of response (DOR)
- Primary outcome: Phase 2: Progression free survival (PFS)
- Primary outcome: Phase 2: Overall survival (OS)

## Indexed commentary on NCT05737706 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05737706